Author

Ana Berrio

Institution: Acadia Pharmaceuticals (United States)

Observed institution: Acadia Pharmaceuticals (United States)

ORCID: 0009-0007-4310-8264

Observed ORCID: 0009-0007-4310-8264

OpenAlex ID: A5034058233

Safety Profile of Pimavanserin Therapy in Elderly Patients with Neurodegenerative Disease-Related Neuropsychiatric Symptoms: A Phase 3B Study

2024 · Gus Alva, Wiesław J. Cubała, et al. · Journal of Alzheimer s Disease · 15

Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis

2022 · Victor Abler, Cecilia Brain, et al. · Frontiers in Neurology · 14

Sedation and sleep safety of pimavanserin for Parkinsons’s disease psychosis: Review and exploratory analysis of clinical study data

2025 · Ana Berrio, Lambros Chrones, et al. · Clinical Parkinsonism & Related Disorders · 2

Pimavanserin safety in adult and elderly patients with neuropsychiatric symptoms related to neurodegenerative disease: An open-label extension study

2025 · Wiesław J Cubała, Ana Berrio, et al. · Journal of Alzheimer s Disease · 1

Safety profile of pimavanserin therapy in elderly patients with neurodegenerative disease‐related neuropsychiatric symptoms: a Phase 3b study

2023 · Gustavo Alva, Wiesław J. Cubała, et al. · Alzheimer s & Dementia · 1

Impact of pimavanserin on cognitive measures in patients with neurodegenerative disease (NDD): results from 4 placebo-controlled clinical studies (2369)

2021 · Clive Ballard, Erin P. Foff, et al. · Neurology · 1

Motor function in patients with neuropsychiatric manifestations of neurodegenerative disease treated with pimavanserin (4531)

2021 · Daniel Weintraub, Erin P. Foff, et al. · Neurology

Works count: 7

Citation count: 34

H-index: 2

I10-index: 2